169 related articles for article (PubMed ID: 38130991)
1. Interferon gamma immunoPET imaging to evaluate response to immune checkpoint inhibitors.
Hackett JB; Ramos N; Barr S; Bross M; Viola NT; Gibson HM
Front Oncol; 2023; 13():1285117. PubMed ID: 38130991
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of an ImmunoPET Tracer for IL-12 in a Preclinical Model of Inflammatory Immune Responses.
Viola NT; Glassbrook JE; Kalluri JR; Hackett JB; Wicker MN; Sternberg J; Gibson HM
Front Immunol; 2022; 13():870110. PubMed ID: 35634303
[TBL] [Abstract][Full Text] [Related]
3. CD4
Kristensen LK; Fröhlich C; Christensen C; Melander MC; Poulsen TT; Galler GR; Lantto J; Horak ID; Kragh M; Nielsen CH; Kjaer A
Theranostics; 2019; 9(26):8221-8238. PubMed ID: 31754392
[TBL] [Abstract][Full Text] [Related]
4. Removal of Fc Glycans from [
White JM; Keinänen OM; Cook BE; Zeglis BM; Gibson HM; Viola NT
Mol Pharm; 2020 Jun; 17(6):2099-2108. PubMed ID: 32330387
[TBL] [Abstract][Full Text] [Related]
5. IFNγ PET Imaging as a Predictive Tool for Monitoring Response to Tumor Immunotherapy.
Gibson HM; McKnight BN; Malysa A; Dyson G; Wiesend WN; McCarthy CE; Reyes J; Wei WZ; Viola-Villegas NT
Cancer Res; 2018 Oct; 78(19):5706-5717. PubMed ID: 30115693
[TBL] [Abstract][Full Text] [Related]
6. Evaluation and selection of a lead diabody for interferon-γ PET imaging.
Rezazadeh F; Ramos N; Saliganan AD; Barr S; Peraino N; Schomburg F; Rancour D; Viola NT
Nucl Med Biol; 2022; 114-115():162-167. PubMed ID: 35753939
[TBL] [Abstract][Full Text] [Related]
7. ImmunoPET imaging of TIGIT in the glioma microenvironment.
Vincze SR; Jaswal AP; Frederico SC; Nisnboym M; Li B; Xiong Z; Sever RE; Sneiderman CT; Rodgers M; Day KE; Latoche JD; Foley LM; Hitchens TK; Frederick R; Patel RB; Hadjipanayis CG; Raphael I; Nedrow JR; Edwards WB; Kohanbash G
Sci Rep; 2024 Mar; 14(1):5305. PubMed ID: 38438420
[TBL] [Abstract][Full Text] [Related]
8. Imaging diagnosis and efficacy monitoring by [
He H; Qi X; Fu H; Xu J; Zheng Q; Chen L; Zhang Y; Hua H; Xu W; Xu Z; Chen X; You Q; Lin J; Huang G; Mao Y; Yu C
Theranostics; 2024; 14(1):392-405. PubMed ID: 38164149
[No Abstract] [Full Text] [Related]
9. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody.
Christensen C; Kristensen LK; Alfsen MZ; Nielsen CH; Kjaer A
Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1302-1313. PubMed ID: 31883023
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive immunoPET imaging of PD-L1 using anti-PD-L1-B11 in breast cancer and melanoma tumor model.
Bansal A; Pandey MK; Barham W; Liu X; Harrington SM; Lucien F; Dong H; Park SS; DeGrado TR
Nucl Med Biol; 2021; 100-101():4-11. PubMed ID: 34119742
[TBL] [Abstract][Full Text] [Related]
11. Local and distant response to intratumoral immunotherapy assessed by immunoPET in mice.
Meyblum L; Chevaleyre C; Susini S; Jego B; Deschamps F; Kereselidze D; Bonnet B; Marabelle A; de Baere T; Lebon V; Tselikas L; Truillet C
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37949616
[TBL] [Abstract][Full Text] [Related]
12. Immuno-PET Monitoring of CD8
Alsaid H; Cheng SH; Bi M; Xie F; Rambo M; Skedzielewski T; Hoang B; Mohanan S; Comroe D; Gehman A; Hsu CY; Farhangi K; Tran H; Sherina V; Doan M; Groseclose MR; Hopson CB; Brett S; Wilson IA; Nicholls A; Ballas M; Waight JD; Jucker BM
Mol Imaging Biol; 2023 Jun; 25(3):528-540. PubMed ID: 36266600
[TBL] [Abstract][Full Text] [Related]
13. A radiopharmaceutical [
Tang Y; Hu Y; Liu W; Chen L; Zhao Y; Ma H; Yang J; Yang Y; Liao J; Cai J; Chen Y; Liu N
Nucl Med Biol; 2019 Mar; 70():23-31. PubMed ID: 30826708
[TBL] [Abstract][Full Text] [Related]
14. Construction and preclinical evaluation of a zirconium-89 labelled monoclonal antibody targeting PD-L2 in lung cancer.
Yao Y; Ren Y; Hou X; Zhu J; Ma X; Liu S; Liu T; Zhang Q; Ma X; Yang Z; Zhu H; Li N
Biomed Pharmacother; 2023 Dec; 168():115602. PubMed ID: 37852097
[TBL] [Abstract][Full Text] [Related]
15. ImmunoPET Imaging with 89Zr-Labeled Atezolizumab Enables In Vivo Evaluation of PD-L1 in Tumorgraft Models of Renal Cell Carcinoma.
Mulgaonkar A; Elias R; Woolford L; Guan B; Nham K; Kapur P; Christie A; Tcheuyap VT; Singla N; Bowman IA; Stevens C; Hao G; Brugarolas J; Sun X
Clin Cancer Res; 2022 Nov; 28(22):4907-4916. PubMed ID: 36074149
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Chelator-to-Antibody Ratio on Development of
Tsai SC; Farn SS; Lo WL; Ou Yang FY; Kang YC; Chen LC; Chen KT; Liao JW; Kung JY; Chen JT; Huang FJ
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38138961
[No Abstract] [Full Text] [Related]
17. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
18. Efficient PD-L1 imaging of murine glioblastoma with FUS-aided immunoPET by leveraging FcRn-antibody interaction.
Chevaleyre C; Novell A; Tournier N; Dauba A; Dubois S; Kereselidze D; Selingue E; Jego B; Maillère B; Larrat B; Nozach H; Truillet C
Theranostics; 2023; 13(15):5584-5596. PubMed ID: 37908736
[No Abstract] [Full Text] [Related]
19. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.
Holland JP; Divilov V; Bander NH; Smith-Jones PM; Larson SM; Lewis JS
J Nucl Med; 2010 Aug; 51(8):1293-300. PubMed ID: 20660376
[TBL] [Abstract][Full Text] [Related]
20. ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma.
Li M; Wei W; Barnhart TE; Jiang D; Cao T; Fan K; Engle JW; Liu J; Chen W; Cai W
Eur J Nucl Med Mol Imaging; 2021 Aug; 48(9):2737-2748. PubMed ID: 33537836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
